A novel isolated phage targeting Pseudomonas aeruginosa demonstrates therapeutic potential
PLOS One · 13.05.2026 · 21 (5) · e0349089
DOI: 10.1371/journal.pone.0349089 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 13.05.2026. Verfasst von Xinjie Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Phage Therapy, Bacteriophages. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changzhou Municipal Sci-Tech Support Program, the Nanjing Medical University–Qilu Clinical Research Fund.
Abstract (Originalsprache)
Pseudomonas aeruginosa is a Gram-negative opportunistic bacterium responsible for severe infections such as pneumonia, septicemia, and keratitis. It poses a significant treatment challenge due to its extensive antibiotic resistance and its capacity to form biofilms, which provide bacterial communities with a protective barrier against antibiotics. An increasing number of studies have identified phage therapy as a potential therapeutic solution amidst the current crisis of antibiotic resistance in medicine. Here, we isolated three novel phages in the campus environment and selected one, PW01, for detailed analysis. Host range was determined against clinical isolates, and biological features were evaluated through growth kinetics and biofilm inhibition assays. Whole genome sequencing and annotation were conducted to confirm its lytic nature. In vivo efficacy was assessed using a murine wound infection model. PW01 displayed a relatively broad host spectrum and effectively suppressed bacterial growth in vitro . It disrupted established biofilms and showed genomic features consistent with a strictly lytic lifestyle. In mice, treatment with PW01 combined with antibiotics resulted in greater bacterial reduction compared with either treatment alone. These findings demonstrate that PW01 possesses both i n vitro and in vivo activity against P. aeruginosa and support the potential of phage-antibiotic combination therapy as an effective strategy against multidrug-resistant (MDR) infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
- Department of Critical Care Medicine, Changzhou Cancer Hospital, Changzhou, China.
- Department of Laboratory Medicine, the First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- The Laboratory Center for Basic Medical Sciences, Nanjing Medical University, Nanjing, China.
- Jintan Hospital Affiliated to Jiangsu University, Changzhou, China.
ORCID-Profile: Huamin Tang
Förderung
- Changzhou Municipal Sci-Tech Support Program
- the Nanjing Medical University–Qilu Clinical Research Fund
Zitieren
APA
Wang, X., Zhang, Z., Garbarino, E., Chen, S., Liu, G., Tang, H., & Xie, H. (2026). A novel isolated phage targeting Pseudomonas aeruginosa demonstrates therapeutic potential. PLOS One, 21(5), e0349089. https://doi.org/10.1371/journal.pone.0349089
Vancouver
Wang X, Zhang Z, Garbarino E, Chen S, Liu G, Tang H, et al. A novel isolated phage targeting Pseudomonas aeruginosa demonstrates therapeutic potential. PLOS One. 2026;21(5):e0349089. doi:10.1371/journal.pone.0349089
BibTeX
@article{Wang2026,
author = {Wang, Xinjie and Zhang, Zhao and Garbarino, Emanuela and Chen, Shuhua and Liu, Genyan and Tang, Huamin and Xie, Hua},
title = {A novel isolated phage targeting Pseudomonas aeruginosa demonstrates therapeutic potential},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0349089},
doi = {10.1371/journal.pone.0349089}
}
EUVIMED